 |
市场调查报告书
商品编码
1444175
糖生物学：市场占有率分析、产业趋势与统计、成长预测（2024-2029）Glycobiology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
糖生物学市场规模预计到 2024 年为 6.2 亿美元，预计到 2029 年将达到 12.4 亿美元，在预测期内（2024-2029 年）增长至 148.7 亿美元，复合年增长率为 %。
与 COVID-19 相关的一些疫苗开发工作主要集中在冠状病毒跨膜刺突 (S) 糖蛋白上，该糖蛋白从病毒表面延伸并介导进入宿主细胞。病毒和宿主细胞之间这种串扰的关键步骤是 S 糖蛋白与人类细胞表面的 ACE2 受体的结合。已知 S-糖蛋白和 ACE2 受体均被广泛糖基化。也就是说，它们含有复杂的共用连接寡糖，称为聚醣。这为疫情期间聚醣的研究开闢了一条有希望的途径。许多研究证明聚醣在 COVID-19感染疾病中很重要。 RIKEN 计算科学中心 (R-CCS) 的研究人员在 2021 年 3 月进行的一项研究发现，当病毒允许 COVID-19 进入人体细胞时，聚醣分子在结构变化中发挥重要作用。 。
根据 2021 年 6 月发表在《分子生物学杂誌》上的一项研究，碳水化合物结合蛋白质参与人类防御和病毒感染能力。用于预防和治疗 COVID-19 的药物包括聚醣抗原、抗聚醣抗体、聚醣结合蛋白质、凝集素抑制剂、多醣、糖苷酶抑制剂和糖苷。因此，上述因素显示全球糖生物学市场受到了COVID-19感染疾病大流行的显着影响。然而，市场目前正在恢復疫情前的状态，预计在预测期内将出现健康成长。
糖生物学市场成长的主要因素是关于分析醣组、聚醣和蛋白质组的新兴技术的研究和开发活动的增加。聚醣通常存在于细胞表面，在人体系统中扮演重要角色。它们是许多遗传疾病的病因，在癌症的发展中也扮演着重要角色。 2021年12月，澳洲格里菲斯大学格氏研究所获得澳洲癌症研究基金会（ACRF）180万美元津贴，成立ACRF国际癌症格氏中心。 2022 年 8 月，以亚伯达大学为中心的泛加拿大卓越中心网络 GlycoNet 将成为加拿大创新基金会专业，继续其研究醣体学以造福人类健康的使命。它获得了美国的投资来自科学倡议基金的1068 万美元。
因此，由于上述因素，预计所研究的市场在预测期内将出现强劲成长。
糖生物学市场趋势
药物发现和开发预计将成为最大的成长领域
随着慢性病负担的增加，开发新药的需求也随之增加。聚醣在细胞间相互作用等生物过程中发挥重要作用，因此在药物开发中具有重要意义。因此，药物是透过修饰糖链来合成的。例如，透明质酸（一种天然存在的Glico单元）在医学上具有广泛的用途。它用于术后伤口，对于治疗骨关节炎至关重要。
根据 2021 年 7 月发表在《国际奈米医学杂誌》上的一项研究，聚醣奈米结构被认为是分子诊断、抗病毒治疗方法和疫苗开发的潜在标靶。在奈米尺度上研究聚醣可以开发疫苗、药物传递系统以及针对病毒和感染疾病的生物分子疗法。可以使用糖蛋白表达系统和基因工程工具来创建基于聚醣的自身佐剂疫苗，以改善免疫抗原性和疫苗反应。因此，糖生物学在疫苗开发中发挥着重要作用，从而促进了该领域的发展。 2022 年 2 月，水谷糖科学基金会收到了 28 个国家的 119 份研究津贴申请。经过仔细评估科学和社会价值、潜力和可行性后，基金会决定向 14 个计划提供约 51 万美元的津贴。因此，预计津贴和核准将促进糖生物学的研究和开发，从而加速该领域的发展。
预计北美将在预测期内主导市场
除了美国慢性病负担日益加重之外，研发活动和政府资助计画的增加预计将为北美地区创造更多机会。 美国9 月，科学书籍、杂誌和电子媒体出版商冷泉港实验室出版社（CSHL Press）宣布成立一个新计画。 InterVenn Biosciences 是一家利用Glico改变医疗保健未来的临床技术公司，参与支持向 CSHL Press 提供的津贴。这表明美国对糖生物学的日益关注，预计将推动未来几年的市场成长。
Vector Laboratories 是创新蛋白质体学和糖生物学解决方案的先驱，于 2022 年 3 月在加州纽瓦克开设了一家新工厂。这些萤光(IF)套件能够对生物系统中的复杂聚醣进行分析和表征，并且完全整合用于检测组织切片中的聚醣表达。随着越来越多的研究人员表示对研究糖生物学的兴趣，糖生物学继续受欢迎，因为它有可能影响肿瘤学等疾病研究的重要领域。Masu。因此，由于上述因素，预计所研究的市场在预测期内将出现强劲成长。
糖生物学产业概述
糖生物学市场竞争适中，有大量公司为市场成长做出了重大贡献。新产品发布、併购、伙伴关係和合作是这些公司实现永续成长的关键策略。市场的主要企业包括安捷伦科技公司、沃特世公司、岛津公司、默克公司和新英格兰生物实验室。
其他福利
- Excel 格式的市场预测 (ME) 表
- 3 个月分析师支持
目录
第一章 简介
- 研究假设和市场定义
- 调查范围
第二章调查方法
第三章执行摘要
第四章市场动态
- 市场概况
- 市场驱动因素
- 增加政府和私人对糖组学和蛋白质组学研究的资助
- 製药和生技公司的研发支出增加
- 市场限制因素
- 产品高成本
- 缺乏熟练的专业人员
- 波特五力分析
- 新进入者的威胁
- 买方议价能力
- 供应商的议价能力
- 替代产品的威胁
- 竞争公司之间的敌意强度
第五章市场区隔
- 副产品
- 酵素
- 装置
- 套件和试剂
- 按用途
- 诊断
- 药物发现与开发
- 肿瘤学
- 免疫学
- 其他用途
- 按最终用户
- 製药和生物技术公司
- 合约研究组织
- 其他最终用户
- 地区
- 北美洲
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他欧洲国家
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 其他亚太地区
- 中东和非洲
- GCC
- 南非
- 其他中东和非洲
- 南美洲
- 巴西
- 阿根廷
- 南美洲其他地区
- 北美洲
第六章 竞争形势
- 公司简介
- Agilent Technologies
- Bruker Corporation
- Danaher Corporation
- Merck KGaA
- New England Biolabs
- ProZyme
- Shimadzu Corporation
- Takara Bio
- Thermo Fisher Scientific
- Waters Corporation
第七章市场机会与未来趋势
The Glycobiology Market size is estimated at USD 0.62 billion in 2024, and is expected to reach USD 1.24 billion by 2029, growing at a CAGR of 14.87% during the forecast period (2024-2029).
Several vaccine development efforts related to COVID-19 primarily focused on the coronavirus transmembrane spike (S) glycoprotein, which extends from the viral surface and mediates host cell entry. A critical step in this crosstalk between the virus and the host cell is the binding of S-glycoprotein to the ACE2 receptor on the surface of human cells. Both S-glycoprotein and ACE2 receptors are known to be extensively glycosylated, i.e., they contain covalently linked complex oligosaccharides called glycans. This makes a promising research path on glycans during the pandemic. Many research studies proved that glycans are crucial in COVID-19 infection. A March 2021 research study by researchers at RIKEN Center for Computational Science (R-CCS) found that glycans sugar molecules play an essential role in the structural changes that occur when the virus causes COVID-19 to invade human cells.
According to a study published in the Journal of Molecular Biology in June 2021, glycan-binding proteins are involved in both human defense and the ability of viruses to infect. Drugs that should be considered for COVID-19 prevention and treatment include glycan antigens, anti-glycan antibodies, glycan-binding proteins, lectin inhibitors, polysaccharides, glycosidase inhibitors, and glycosides. Thus, the above-mentioned factors state that the global glycobiology market was significantly impacted by the COVID-19 pandemic. However, the market is currently gaining its pre-pandemic nature and is expected to witness healthy growth over the forecast period.
The major factor responsible for the growth of the glycobiology market is the increasing research and development activities about glycomes and emerging technology for analyzing glycans and proteomes. Glycans, generally present on the cell surface, play a crucial role in the body system. They are responsible for many hereditary diseases and have a vital role in cancer development. In December 2021, Griffith University's Institute for Glycomics of Australia received a grant of USD 1.80 million from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. In August 2022, GlycoNet, a pan-Canadian network of Centers of Excellence centered at UAlberta, received a USD 10.68 million investment from the Canadian Foundation for Innovation's Major Science Initiative Fund to continue its mission of researching glycomics for the benefit of human health.
Thus, owing to the above-mentioned factors, the market studied is believed to witness strong growth over the forecast period.
Glycobiology Market Trends
Drug Discovery and Development is Expected to be the Largest Growing Segment
As the burden of chronic diseases increases, the need to develop new drugs is also increasing. Glycans play a key role in biological processes, such as cell-cell interaction, and thus have immense importance in drug development. Therefore, glycan chains are modified to synthesize drugs. For instance, hyaluronan, a naturally occurring disaccharide unit of glycosaminoglycan, has wide applications in medicine. It is used in post-surgical wounds and is essential in osteoarthritis treatment.
According to a study published in the International Journal of Nanomedicine in July 2021, glycan nanostructures are thought to be potential targets for molecular diagnosis, antiviral therapeutics, and vaccine development. The development of vaccines, drug delivery systems, and biomolecular therapeutics for viruses and infectious diseases can be enabled by studying glycans at the nanoscale. Glycan-based self-adjuvanted vaccines can be created to improve immunogenicity and vaccine response using glycoprotein expression systems and genetic engineering tools. Thus, glycobiology plays an essential role in the development of vaccines, thereby boosting the growth of the segment. In February 2022, Mizutani Foundation for Glycoscience received 119 research grant applications from 28 countries. After careful evaluation of scientific and social merit, potentiality, and feasibility, the Foundation decided to award grants of approximately USD 0.51 million to 14 projects. Thus, grants and approvals are expected to boost research and development in glycobiology, thereby boosting the growth of the segment.
North America is Expected to Dominate the Market Over the Forecast Period
The increasing research and development activities and government funding programs, along with the growing burden of chronic diseases in the United States, are expected to create more opportunities for the North America region. In September 2022, Cold Spring Harbor Laboratory Press (CSHL Press), a publisher of scientific books, journals, and electronic media established a new program to provide access to the field of glycobiology, which is developing rapidly across the United States. InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, is involved in supporting the grant for CSHL Press. This indicates the increasing focus on glycobiology which is expected to fuel the market growth in coming years across the United States.
In March 2022, Vector Laboratories, the pioneer of innovative proteomic and glycobiology solutions, opened its new facility in Newark, California. These immunofluorescence (IF) kits enable the profiling and characterization of complex glycans in biological systems and are completely integrated for the detection of glycan expression in tissue sections. As more researchers express interest in studying glycobiology due to the potential impact it may have on important areas of illness research like oncology, glycan research is continuing to gain popularity. Hence, owing to the above-mentioned factors, the market studied is expected to witness strong growth over the forecast period.
Glycobiology Industry Overview
The glycobiology market is moderately competitive, with the presence of a considerable number of companies that significantly contribute to the market growth. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies adopted by these companies for sustainable growth. Some key companies in the market include Agilent Technologies, Waters Corporation, Shimadzu Corporation, Merck KGaA, and New England Biolabs, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
- 4.2.2 Growing R&D Expenditures by Pharmaceutical and Biotechnology Companies
- 4.3 Market Restraints
- 4.3.1 High Product Cost
- 4.3.2 Low Availability of Skilled Professionals
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size - Value in USD million)
- 5.1 By Product
- 5.1.1 Enzymes
- 5.1.2 Instruments
- 5.1.3 Kits and Reagents
- 5.2 By Application
- 5.2.1 Diagnostics
- 5.2.2 Drug Discovery and Development
- 5.2.3 Oncology
- 5.2.4 Immunology
- 5.2.5 Other Applications
- 5.3 By End User
- 5.3.1 Pharmaceutical and Biotechnology Companies
- 5.3.2 Contract Research Organizations
- 5.3.3 Other End Users
- 5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
- 5.4.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Agilent Technologies
- 6.1.2 Bruker Corporation
- 6.1.3 Danaher Corporation
- 6.1.4 Merck KGaA
- 6.1.5 New England Biolabs
- 6.1.6 ProZyme
- 6.1.7 Shimadzu Corporation
- 6.1.8 Takara Bio
- 6.1.9 Thermo Fisher Scientific
- 6.1.10 Waters Corporation
